Search
Research
In vitro antibacterial activity of Western Australian honeys, and manuka honey, against bacteria implicated in impetigoImpetigo is a contagious skin disease caused by Staphylococcus aureus and Streptococcus pyogenes. Without treatment, impetigo may be recurrent, develop into severe disease, or have serious, life-threatening sequelae. Standard treatment consists of topical or systemic antibiotic therapy (depending on severity), however, due to antibiotic resistance some therapies are increasingly ineffective.
Research
Clindamycin adjunctive therapy for severe Staphylococcus aureus treatment evaluation (CASSETTE)-an open-labelled pilot randomized controlled trialCombination antibiotic therapy with an antitoxin agent, such as clindamycin, is included in some guidelines for severe, toxin-mediated Staphylococcus aureus infections. The evidence to support this practice is currently limited to in vitro, animal and observational human case-series data, with no previous randomized controlled trials (RCTs).
Research
Burden of skin disease in two remote primary healthcare centres in northern and central AustraliaSkin infections are an under-appreciated and dominant reason for presentation to primary healthcare centres in these indigenous communities
Research
Lessons learned from a hospital-wide review of blood stream infections for paediatric central line-associated blood stream infection preventionHealth care-associated bacteraemia has a significant impact on child health, exceeding the number of community-acquired bacteraemia at our hospital
Research
Comparison of three methods for the recovery of skin pathogens from impetigo swabs collected in a remote community of Northern Territory, AustraliaImmediate plating of impetigo swabs is the gold standard for bacterial recovery but is rarely feasible in remote regions.
Research
Australian Group on Antimicrobial Research surveillance outcome programs - bloodstream infections and antimicrobial resistance patterns from patients less than 18 years of ageFrom 1 January 2020 to 31 December 2021, thirty-eight institutions across Australia submitted data to the Australian Group on Antimicrobial Resistance (AGAR) from patients aged < 18 years (AGAR-Kids). Over the two years, 1,679 isolates were reported from 1,611 patients. This AGAR-Kids report aims to describe the population of children and adolescents with bacteraemia reported to AGAR and the proportion of resistant isolates.
Research
Dedicated paediatric Outpatient Parenteral Antimicrobial Therapy medical support: a pre-post observational studyWe examined the impact of introducing a dedicated team to OPAT, to define the role of increased medical oversight in improving patient outcomes in this cohort.
Research
Evaluation of Pediatric HIV Postexposure Prophylaxis Guideline Following Child Sexual Assault in Western AustraliaHIV postexposure prophylaxis (PEP) following child sexual assault (CSA) is recommended in select cases. High rates of poor adherence to PEP are reported. We evaluated adherence to the recommended management of children following CSA at the tertiary pediatric facility in Western Australia and compared our approach with international guidelines.
News & Events
The Kids researchers named as finalists in 2023 Premier’s Science AwardsFive The Kids Research Institute Australia researchers working across diverse and highly impactful areas of child health research have been named as finalists for the 2023 Premier’s Science Awards.
Research
Optimisation of sampling for a new Skin Microbiome assayAsha Janessa Tim Bowen Pickering Barnett BA MBBS DCH FRACP PhD GAICD FAHMS OAM BSc PhD PhD Head, Healthy Skin and ARF Prevention Senior Research